Outcomes of Therapeutic Plasma Exchange; One Year Single Center Experience

Ghonemy, Tarek A

doi:10.15406/unoaj.2016.03.00096

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myasthenia Gravis (MG) is an autoimmune disease characterized by presence of antibodies that attacking postsynaptic nicotinic acetylcholine receptors and presented with fluctuating weakness that may progress to life-threatening complications [20] . The study included 4 cases with myasthenia gravis that showed marvelous response after starting TPE (100% remission rate).…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Plasma Exchange in Tanta University Hospitals, Single Center Experience

El-Attar¹,

Allam

2019

The Medical Journal of Cairo University

View full text Add to dashboard Cite

Background: Therapeutic Plasma Exchange (TPE) is effective therapeutic procedure in treating diverse diseases. Aim of Study:To evaluate the outcomes of TPE in different diseases in our department. Patients and Methods:Retrospective study of patients referred for TPE during last five years period. We reviewed the demographic, clinical indications, number of sessions, volume of exchanged plasma, patient response and complications during or after the procedure and descriptive statisticalanalysis was performed. Results:The study included 109 patients recorded during the last 5 years period. The indications for TPE were Gullian-Baree in 28 patients with response in (21/28 pateints), thrombotic microangiopathy in 27 patients with response in (19/27) patients, SLE in 22 patients with response in (16/22), Cryoglobinemia in 12 patients with response in (10/12), RPGN in 5 patients with response in (4/5) patients, hyperviscosity in 6 patients, mythenia gravis in 4 patients, renal transplantation in 3 patients, dermatomyocitis in one patient and autoimmune hemolytic anemia in one patient with complete response in all patients of these later diseases. The main complications of the procedure were muscle cramps induced by hypocalcemia (n=10, 9%), allergic reactions (n=9, 8%), hypotension (n=7, 6%), fever (n=4, 3.6%), loss of consciousness (n=2, 1.8%), convulsions (n=2, 1.8%), catheter related hematoma (n=1, 0.9%), bleeding from AV fistula (n=1, 0.9%). Conclusion:Our experience in therapeutic plasma exchange showed favorable results in different immunological and non-immunological diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic Plasma Exchange in Tanta University Hospitals, Single Center Experience

El-Attar¹,

Allam

2019

The Medical Journal of Cairo University

View full text Add to dashboard Cite

show abstract

“…Ghonemy TA and colleagues [9] noted that therapeutic plasmapheresis is almost safe and effective adjuvant treatment for several diseases especially autoimmune diseases, like MG. Plasmapheresis achieved immediate improvement of MG symptoms, and, while it made patients attentive to the course of their disease, it also helped them realize that there was a possibility of relief.…”

Section: Introductionmentioning

confidence: 99%

Determinants of quality of life changes with plasmapheresis in patients with myasthenia gravis

Al-Ahmer

Elshony

2021

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background Immunomodulation, including IVIG and plasma exchange, is useful for a crisis or severe exacerbation. Plasma exchange may be slightly faster and more effective in a myasthenic crisis than IVIG. The aim of the current study was to determine the changes in the quality of life (QOL) after plasmapheresis and factors influencing these changes. Results This study was conducted on 98 MG patients diagnosed as moderate to severe myasthenia gravis (according to Myasthenia Gravis Foundation of America classification), 81 patients received alternate day 5 sessions plasmapheresis (TPE group) and 17 patients were on medical treatment only (control group). All patients were subjected to full history, through clinical neurological evaluation and scored with quantitative myasthenia gravis (QMG) score for MG severity at start and after 1 m. Both groups completed the QOL questionnaire at baseline and after 1 month. The MG-QOL-15 scores were computed and we analyzed the change in the QOL scores from baseline to after plasmapheresis groups and compared it with the results for the control group. The scores in QOL scales had significantly decreased after plasmapheresis, and the improvement in QOL scores had a good correlation with the decrease in QMGS. The improvement in QOL and QMG was significantly correlated with younger age, female gender, shorter duration of the illness, presence of AchR antibodies, antibody titer, and thymus hyperplasia. Conclusion Plasmapheresis is effective in improving quality of life in myasthenia gravis patients and this improvement influenced by age, gender, duration of illness, presence of AchR antibodies and their titer, and the thymus pathology.

show abstract

Therapeutic Plasma Exchange – A 2 Years Experience at a Tertiary Care Centre in Mumbai, Maharashtra, India

Udani¹,

Neogi²,

Dhote³

et al. 2021

jemds

View full text Add to dashboard Cite

BACKGROUND Therapeutic plasma exchange is a process where the blood collected from patient is passed through an apheresis instrument where the plasma is removed and discarded and reinfusion of blood cells done with replacement fluids like plasma or albumin to the patient.1 It is to remove pathogenic autoantibodies, immune complexes, cryoglobulins and toxins present in the plasma. Plasma exchange is considered effective and cheaper immunomodulatory treatment when compared to intravenous immunoglobulin (IVIG). 2 We present our institutional experience with therapeutic plasma exchange (TPE) in treatment of various non-neurological and neurological diseases. Our study was conducted to assess the indications, complications and outcome of TPE in the treatment of patients. METHODS A retrospective study of TPE procedures was carried out in the Department of Immunohaematology and blood transfusion, M.G.M Medical College and Hospital, Navi Mumbai from June 2018 to June 2020. A total of 45 procedures were performed among 13 patients between 4 years of age to 66 years of age. Clinical parameters were checked, and laboratory investigations were done before the procedure. Data was collected from the requisition forms by the clinicians and the apheresis database. RESULTS A total of 47 procedures were carried out among 13 patients. TPE is a safe and effective procedure for treating patients with neurologic and non-neurological diseases. Most common indication was Guillain Barre syndrome followed by myasthenia gravis. Incidence of adverse reactions was 7.6 %. CONCLUSIONS TPE is a safe and effective procedure for treating patients with neurologic and nonneurological diseases. It benefited 10 out of 13 patients, and they showed complete recovery. KEY WORDS Therapeutic Plasma Exchange, Guillain Barre syndrome

show abstract

Outcomes of Therapeutic Plasma Exchange; One Year Single Center Experience

Cited by 3 publications

References 32 publications

Therapeutic Plasma Exchange in Tanta University Hospitals, Single Center Experience

Therapeutic Plasma Exchange in Tanta University Hospitals, Single Center Experience

Determinants of quality of life changes with plasmapheresis in patients with myasthenia gravis

Therapeutic Plasma Exchange – A 2 Years Experience at a Tertiary Care Centre in Mumbai, Maharashtra, India

Contact Info

Product

Resources

About